⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RNTX News
Rein Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
RNTX
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
globenewswire.com
RNTX
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
RNTX
Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications
globenewswire.com
RNTX
Form 8-K
sec.gov
RNTX
Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries
globenewswire.com
RNTX
Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom
globenewswire.com
RNTX
Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
globenewswire.com
RNTX
Form 8-K
sec.gov
RNTX
Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock
globenewswire.com
RNTX